Starting tomorrow, a group from Columbia Technology Ventures (CTV), the technology transfer office at Columbia University, will host a booth at the 2013 International CES in Las Vegas, Nevada. The booth will include highlights from four of Columbia University’s startup portfolio companies, along with other innovative technologies available for licensing from CTV.
Cellrox Ltd. announced today the signing of a worldwide exclusive agreement with Columbia University to license certain mobile technology developed at Columbia that will enables corporate IT departments to securely accommodate the Bring Your Own Device (BYOD) trend.
Columbia University grants Health Fidelity exclusive rights to robust portfolio of patents, software code, and trademarks for commercialization of MedLEE, clinical NLP technology to improve usability of health information and support data-driven healthcare.
Columbia engineers develop new bioengineering approach to study stem cell function and factors that could lead to birth defects and disease.
China Institute of Strategy and Management Lanmeng Investment Co., Ltd., and Columbia University announced today that they have entered into research and license agreements, granting worldwide exclusive rights to a portfolio of certain Columbia intellectual property that may lay the foundation for new approaches in the diagnosis and treatment of a variety of human autoimmune diseases and a wide range of other human immunologic relevant disorders.
A team of scientists from Columbia University, Georgia Institute of Technology and the University of Granada in Spain have successfully reconstructed active enzymes from four-billion-year-old extinct organisms. By measuring the properties of these enzymes, they could examine the conditions in which the extinct organisms lived. The results shed new light on how life has adapted to changes in the environment from ancient to modern Earth.
A new mobile application provides users with simplified access to vast libraries of images and information that up until now were tapped mainly by earth and environmental scientists. The EarthObserver App, for the iPhone, iPad or iPod Touch, displays natural features and forces on land, undersea and in the air. Created at Columbia University’s Lamont-Doherty Earth Observatory, it works on an intuitive level with touches of the fingers, drawing on dozens of frequently updated databases from institutions throughout the world.
Alkeus Pharmaceuticals and Columbia University announced today that they have entered into a license agreement for a set of potential therapies for the treatment of dry age-related macular degeneration (dry-AMD), Stargardt disease, and other degenerative diseases of the eye. Left untreated, these conditions often lead to impaired vision and even blindness.
Columbia University and Neuromatters, LLC announced that they have entered into an agreement to develop a novel brain-computer interface (BCI) technology for rapid identification of relevant images.
New understanding could lead to novel therapies for addressing autoimmune disease and organ transplant rejection without nonspecific suppression of the immune system.
\Ascent Scientific and Columbia University today announced that they have entered into a license agreement for RuBi-Glutamate, RuBi-GABA and RuBi-4AP, novel light-sensitive, caged ligands that have broad applicability for biological research.
Columbia scientists working to combat injury-related depression, substance abuse and suicide due to unremitting, persistent pain may have discovered a new way of treating that pain: a powerful analgesic dubbed N60 that leads to neither tolerance nor addiction.
Columbia University announced that it has licensed a computer graphics technology to Adobe Systems that can simulate the natural movement and flexibility of strands as fine as a single human hair.
Columbia University and Global Research Technologies (GRT) announced that they have entered into a worldwide research collaboration and cross-licensing agreement for technology that extracts and captures carbon dioxide (CO2) from the atmosphere.
Tocris Bioscience and Columbia University today announced that they have expanded their license agreement to include RuBi-Glutamate and RuBi-4AP, two additional novel caged compounds with significant applications for basic science research.
Columbia University and FairChoice Systems, Inc. have signed a multi-year commercialization agreement that will bring to market a cost-effective, online student health information system developed and implemented by Columbia University’s own Student Health Services.
Columbia University and Ascent Scientific announced that they have entered into a license agreement for FFN511, a novel fluorescent probe for optical imaging and measurement of synaptic activity in the brain.
Columbia University Science & Technology Ventures announced that it has licensed a pathogen detection technology called MassTag PCR to Vimta Labs to develop clinical diagnostics for patients in India.
Columbia University Science and Technology Ventures (STV) announced today that PCAsso Diagnostics, the exclusive licensee of retinal imaging technology developed at Columbia, is the winner of the Most Innovative Technology Award from the 2009 SmartStart UNYTECH Ventures Forum.
Columbia University Science & Technology Ventures and EndoRobotics, Inc. have entered into an exclusive license agreement to develop and commercialize a micro-robotic imaging and surgical device platform designed to reduce the complexity of minimally invasive surgical (MIS) procedures and improve patient outcomes.
Tocris Bioscience (www.tocris.com) today announced that they have entered into a license agreement with Columbia University Science & Technology Ventures (STV) for RuBi-GABA, a novel caged-GABA compound with significant applications for basic science research.
Columbia University Science and Technology Ventures announced that it has signed a worldwide exclusive license agreement with PCAsso Diagnostics, LLC to develop and market a novel imaging technology for diagnosis of vascular leakage disorders of the retina.
Columbia University Science & Technology Ventures has announced that it has signed an exclusive license agreement with Vital View Limited to bring to market a medical device technology that aims to improve the success of in vitro fertilization (IVF) procedures.
Columbia University Science & Technology Ventures (STV) announced today that Intelligent Bio-Systems, Inc. (IBS), exclusive licensee of certain Columbia DNA sequencing patents, has closed a round of financing led by Norwich Ventures of Waltham, Massachusetts.
Columbia University's Science & Technology Ventures announced that it has signed a license agreement with Stockbridge Pharmaceuticals, Inc. to commercialize a novel small molecule-based approach, developed in collaboration with the University of Nebraska, for the targeted treatment of various cancers.
Columbia University's Science & Technology Ventures (STV) announced that it has licensed MedLEE, a robust and proven natural language processing technology, to Columbia spin-out, NLP International Corporation.
Columbia University spin-off company, StackSafe, Inc., is the winner of the 2008 National University Start-Up Competition. Beating out more than 400 entrants from across the country, StackSafe was awarded first prize after a rigorous assessment by an online panel of over 300 venture capitalists, angel investors, and university judges.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right